Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
The Central Dogma01:20

The Central Dogma

The central dogma explains the flow of genetic information from DNA nucleotides to the amino acid sequence of proteins.
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
Modern Molecular Taxonomy01:29

Modern Molecular Taxonomy

Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

For Autoimmune Ills, Biologics Bring Promise-And Problems.

Managed care (Langhorne, Pa.)·2017
Same author

Biosimilar Research Proceeds in Cancer, RA, and Hep B.

Managed care (Langhorne, Pa.)·2016
Same author

Biosimilars in Development Near End of Phase 3 Trials.

Managed care (Langhorne, Pa.)·2016
Same author

Digital Health Technology Adoption Depends On Tech Comfort Level, Willingness to Pay.

Managed care (Langhorne, Pa.)·2016
Same author

New Cancer Drugs Shine, but Costs May Dim Luster.

Managed care (Langhorne, Pa.)·2015
Same author

Sure, They're Cool, but Will Smart Wearables Ever Live Up to Their Potential?

Managed care (Langhorne, Pa.)·2015
Same journal

Big pharma moves into biologics.

Biotechnology healthcare·2013
Same journal

Study: High Copayments Cut Biodrug Use up to 21 Percent.

Biotechnology healthcare·2013
Same journal

Avian flu and the quest for immunity: not just chicken feed.

Biotechnology healthcare·2013
Same journal

Variety of Biotech Therapies, Uses Take Prominence Among ASCO Presentations.

Biotechnology healthcare·2013
Same journal

Opening the door to follow-on proteins?

Biotechnology healthcare·2013
Same journal

On specialty pharmaceuticals: reflections of a second-year medical student.

Biotechnology healthcare·2013
See all related articles

Related Experiment Video

Updated: May 14, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Gene-based Diagnostics: Ready for Prime Time?

Katherine T Adams

    Biotechnology Healthcare
    |February 21, 2013
    PubMed
    Summary
    This summary is machine-generated.

    Gene-based diagnostic tests offer early disease detection and treatment response prediction. However, widespread physician adoption faces significant challenges.

    More Related Videos

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
    11:15

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

    Published on: September 20, 2016

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
    05:53

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

    Published on: June 21, 2018

    Related Experiment Videos

    Last Updated: May 14, 2026

    Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
    13:24

    Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

    Published on: April 11, 2016

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
    11:15

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

    Published on: September 20, 2016

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
    05:53

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

    Published on: June 21, 2018

    Area of Science:

    • Genetics
    • Molecular Diagnostics
    • Personalized Medicine

    Background:

    • Growing interest in gene-based diagnostics for early disease detection.
    • Potential for predicting patient response to specific drugs and treatments.
    • Current limitations hindering widespread clinical implementation.

    Purpose of the Study:

    • To explore the development of gene-based diagnostic tests.
    • To assess the potential of these tests in clinical practice.
    • To identify barriers to physician adoption.

    Main Methods:

    • Review of current research in gene-based diagnostics.
    • Analysis of technological advancements.
    • Examination of regulatory and clinical integration challenges.

    Main Results:

    • Gene-based tests show promise for earlier disease detection.
    • Predictive capabilities for treatment response are advancing.
    • Significant hurdles remain for routine physician use.

    Conclusions:

    • Gene-based diagnostics are a rapidly evolving field with high potential.
    • Widespread clinical adoption requires overcoming technical and practical challenges.
    • Further research and development are needed to facilitate physician integration.